JP2017523188A5 - - Google Patents

Download PDF

Info

Publication number
JP2017523188A5
JP2017523188A5 JP2017504752A JP2017504752A JP2017523188A5 JP 2017523188 A5 JP2017523188 A5 JP 2017523188A5 JP 2017504752 A JP2017504752 A JP 2017504752A JP 2017504752 A JP2017504752 A JP 2017504752A JP 2017523188 A5 JP2017523188 A5 JP 2017523188A5
Authority
JP
Japan
Prior art keywords
dlbcl
use according
modification
amino acid
bcl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017504752A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017523188A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/043300 external-priority patent/WO2016019341A1/en
Publication of JP2017523188A publication Critical patent/JP2017523188A/ja
Publication of JP2017523188A5 publication Critical patent/JP2017523188A5/ja
Pending legal-status Critical Current

Links

JP2017504752A 2014-08-01 2015-07-31 Btk阻害剤を伴う治療に対するdlbclの応答を予測するためのバイオマーカー Pending JP2017523188A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201462032430P 2014-08-01 2014-08-01
US62/032,430 2014-08-01
US201562119668P 2015-02-23 2015-02-23
US62/119,668 2015-02-23
US201562127484P 2015-03-03 2015-03-03
US62/127,484 2015-03-03
PCT/US2015/043300 WO2016019341A1 (en) 2014-08-01 2015-07-31 Biomarkers for predicting response of dlbcl to treatment with a btk inhibitor

Publications (2)

Publication Number Publication Date
JP2017523188A JP2017523188A (ja) 2017-08-17
JP2017523188A5 true JP2017523188A5 (enExample) 2018-09-13

Family

ID=55179406

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017504752A Pending JP2017523188A (ja) 2014-08-01 2015-07-31 Btk阻害剤を伴う治療に対するdlbclの応答を予測するためのバイオマーカー

Country Status (13)

Country Link
US (1) US20160032404A1 (enExample)
EP (1) EP3185870A4 (enExample)
JP (1) JP2017523188A (enExample)
KR (1) KR20170042614A (enExample)
CN (1) CN106714804A (enExample)
AU (1) AU2015296010A1 (enExample)
BR (1) BR112017001677A2 (enExample)
CA (1) CA2955744A1 (enExample)
IL (1) IL250221A0 (enExample)
MX (1) MX2017001302A (enExample)
RU (1) RU2017106794A (enExample)
SG (1) SG11201700774UA (enExample)
WO (1) WO2016019341A1 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2350075T1 (sl) 2008-09-22 2014-06-30 Array Biopharma, Inc. Substituirane imidazo (1,2b)piridazinske spojine kot Trk kinazni inhibitorji
SG10201914059WA (en) 2008-10-22 2020-03-30 Array Biopharma Inc Substituted pyrazolo[1,5-a]pyrimidine compounds as trk kinase inhibitors
AR077468A1 (es) 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
EP2918588B1 (en) 2010-05-20 2017-05-03 Array Biopharma, Inc. Macrocyclic compounds as TRK kinase inhibitors
NZ604040A (en) 2010-06-03 2015-02-27 Pharmacyclics Inc The use of inhibitors of bruton’s tyrosine kinase (btk)
KR20150032340A (ko) 2012-07-24 2015-03-25 파마시클릭스, 인코포레이티드 브루톤 티로신 키나제(btk)의 억제제에 대한 내성과 관련된 돌연변이
WO2016071770A2 (en) * 2014-11-05 2016-05-12 Janssen Pharmaceutica Nv Biological markers for identifying ibrutinib resistance in patients having mantle cell lymphoma and methods of using the same
US10799505B2 (en) 2014-11-16 2020-10-13 Array Biopharma, Inc. Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate
MA54411B1 (fr) 2015-04-06 2023-11-30 Janssen Pharmaceutica Nv Compositions contenant de l'ibrutinib
JP2018534296A (ja) 2015-10-26 2018-11-22 ロクソ オンコロジー, インコーポレイテッドLoxo Oncology, Inc. Trk阻害薬耐性がんにおける点変異およびそれに関連する方法
MX386416B (es) 2016-04-04 2025-03-18 Loxo Oncology Inc Formulaciones liquidas de (s)-n-(5-((r)-2-(2,5-difluorofenil)-pirrolidin-1-il)-pirazolo[1,5-a]pirimidin-3-il)-3-hidroxipirrolidina-1-carboxamida.
US10045991B2 (en) 2016-04-04 2018-08-14 Loxo Oncology, Inc. Methods of treating pediatric cancers
HUE063877T2 (hu) 2016-05-18 2024-02-28 Loxo Oncology Inc (S)-N-(5-((R)-2-(2,5-dlfluorofenil)pirolidin-1-il)plrazolo[1,5-A]pirimidin-3-il) -3-hidroxipirolidin-1-karboxamid elõállítása
JOP20190092A1 (ar) 2016-10-26 2019-04-25 Array Biopharma Inc عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها
JP7356351B2 (ja) * 2016-12-12 2023-10-04 エクセラ・バイオサイエンシーズ・インコーポレイテッド マイクロキャピラリーアレイを使用したスクリーニングのための方法およびシステム
US11085039B2 (en) 2016-12-12 2021-08-10 xCella Biosciences, Inc. Methods and systems for screening using microcapillary arrays
WO2018125832A1 (en) 2016-12-30 2018-07-05 xCella Biosciences, Inc. Multi-stage sample recovery system
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
EP3612192A4 (en) * 2017-06-08 2020-05-27 Enlivex Therapeutics Ltd. THERAPEUTIC APOPTOTIC CELLS FOR CANCER THERAPY
CZ2017787A3 (cs) 2017-12-08 2019-06-19 Zentiva, K.S. Farmaceutické kompozice obsahující ibrutinib
CN112292117B (zh) * 2018-06-15 2024-06-07 詹森药业有限公司 包含依鲁替尼的配制品/组合物
GB2577909B (en) * 2018-10-10 2020-11-18 Symetrica Ltd Gamma-ray spectrum classification
MX2021006368A (es) * 2018-11-30 2021-10-13 Janssen Biotech Inc Métodos para tratar el linfoma folicular.
ES3039910T3 (en) 2018-12-06 2025-10-27 Xcella Biosciences Inc Lateral loading of microcapillary arrays
WO2021087044A1 (en) * 2019-10-30 2021-05-06 Celgene Corporation Methods for predicting responsiveness of lymphoma to drug and methods for treating lymphoma
CA3209784A1 (en) * 2021-02-03 2022-08-11 Curis Inc. Biomarkers for fimepinostat therapy
WO2023275330A1 (en) * 2021-06-30 2023-01-05 Janssen Pharmaceutica Nv Treatments for diffuse large b-cell lymphoma
MX2023015147A (es) * 2021-06-30 2024-04-01 Janssen Pharmaceutica Nv Inhibidores de la tirosina quinasa de bruton y métodos de su uso.
JP7423090B2 (ja) * 2022-04-07 2024-01-29 学校法人藤田学園 不明熱患者のb細胞リンパ腫診断補助キットおよび情報提供方法
WO2025080543A1 (en) * 2023-10-09 2025-04-17 Bristol-Myers Squibb Company Methods for predicting responsiveness of lymphoma to drug and methods for treating lymphoma
JP7696987B1 (ja) * 2023-12-22 2025-06-23 東洋鋼鈑株式会社 遺伝子変異を検出する方法
JP7698850B1 (ja) * 2023-12-22 2025-06-26 東洋鋼鈑株式会社 遺伝子変異評価用キット

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ604040A (en) * 2010-06-03 2015-02-27 Pharmacyclics Inc The use of inhibitors of bruton’s tyrosine kinase (btk)
CA2841142C (en) * 2010-06-23 2020-12-15 Ryan D. Morin Biomarkers for non-hodgkin lymphomas and uses thereof
EP2771010A4 (en) * 2011-10-19 2015-04-01 Pharmacyclics Inc USE OF BRUTON TYROSINE KINASE (BTK) INHIBITORS
EP2770830A4 (en) * 2011-10-28 2015-05-27 Celgene Avilomics Res Inc METHODS OF TREATING A DISEASE OR DISEASE ASSOCIATED WITH TYROSINE KINASE BTK (BRUTON'S TYROSINE KINASE)
EA201492082A1 (ru) * 2012-06-04 2015-03-31 Фармасайкликс, Инк. Кристаллические формы ингибитора тирозинкиназы брутона
KR20150032340A (ko) * 2012-07-24 2015-03-25 파마시클릭스, 인코포레이티드 브루톤 티로신 키나제(btk)의 억제제에 대한 내성과 관련된 돌연변이
AU2014205577A1 (en) * 2013-01-10 2015-05-28 Nimbus Iris, Inc. IRAK inhibitors and uses thereof

Similar Documents

Publication Publication Date Title
JP2017523188A5 (enExample)
RU2017106794A (ru) Биомаркеры для прогнозирования ответа двккл на лечение с использованием ингибитора втк
EA201890006A1 (ru) Применение экзосом для лечения болезни
Wang et al. Gene expression profiling identifies IRF4-associated molecular signatures in hematological malignancies
EA201992063A1 (ru) СВЯЗЫВАЮЩИЕ ErbB-2 И ErbB-3 БИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА ДЛЯ ПРИМЕНЕНИЯ ДЛЯ ЛЕЧЕНИЯ КЛЕТОК, КОТОРЫЕ СОДЕРЖАТ СЛИТЫЙ ГЕН NRG-1
MY185845A (en) Icos binding proteins
MX2017014381A (es) Metodos terapeuticos y diagnosticos para cancer.
JP2014523751A5 (enExample)
MX2017014736A (es) Metodos terapeuticos y diagnosticos para cancer.
EP2568996A4 (en) INNOVATIVE DISCOVERY OF THERAPEUTIC, DIAGNOSTIC AND ANTIBODY COMPOSITIONS IN CONNECTION WITH PROTEIN FRAGMENTS OF PHENYLALANYL BETA-TRNA SYNTHETASES
WO2017116817A3 (en) Testing of medicinal drugs and drug combinations
AU2016304856A8 (en) Mechanism of resistance to BET bromodomain inhibitors
EP3869198A3 (en) Reagents and methods for breast cancer detection
EA202092156A1 (ru) Модифицированные олигонуклеотиды и способы применения в лечении таупатий
JP2017506259A5 (enExample)
WO2018026969A3 (en) Plazomicin antibodies and methods of use
TWD195924S (zh) 寶石
BR112018076287A2 (pt) métodos e composições para o tratamento de doença celíaca, sensibilidade ao glúten não celíaca e doença celíaca refratária
SG10201903424RA (en) ANTI HUMAN Gas6 MONOCLONAL ANTIBODY
Zhang et al. Heterocyclic compounds and uses thereof
CO2019002853A2 (es) Composiciones de tesofensina
EP3733861A4 (en) IN VITRO PROTEIN SYNTHESIS SYSTEM, KIT AND ITS PREPARATION PROCESS
WO2016096640A3 (en) Anti-cxcl12 antibody molecules and their uses
PAUL An In-depth Description and Detailed Analysis of Implementing Alternative Methods of Financing Software
Youlatos et al. Early Colobine Adaptations: Functional Morphology of the Elbow in Microcolobus from Nakali, Kenya